Business Wire

CA-CLICKHOUSE,-INC.

4.10.2022 16:01:41 CEST | Business Wire | Press release

Share
Announcing ClickHouse Cloud: Democratizing lightning-fast insights and analytics

Today, ClickHouse, Inc. announced the launch of ClickHouse Cloud, a lightning-fast cloud-based database that simplifies and accelerates insights and analytics for modern digital enterprises. With no infrastructure to manage, ClickHouse Cloud architecture decouples storage and compute and scales automatically to accommodate modern workloads, so users do not have to size and tune their clusters to achieve blazing-fast query speeds.

Historically, data infrastructure and analytics solutions have been expensive and difficult to manage. Companies frequently bore the expense of specialized experts and infrastructure teams, only to receive unacceptable performance in return, as legacy solutions struggled to scale. The introduction of ClickHouse Cloud, built by the creators of the much-loved open source project, brings enterprise-grade data analytics and lightning-fast insights to the masses. A ClickHouse Cloud user can log in and launch a new service with a few clicks, and start analyzing their own data in under five minutes.

ClickHouse Cloud, initially released in Beta on AWS, and coming soon on other cloud providers, is highly available and secure by default, so users can focus on developing business-critical applications without the overhead of tuning cluster topology settings. Developers can adopt the latest ClickHouse capabilities, and never have to worry about time-consuming manual upgrades. Built on strong security and privacy fundamentals, the service is already SOC 2 Type I and GDPR compliant, with additional certifications in progress.

ClickHouse Cloud is fully self-service, with a simple, transparent pricing model that allows users to pay only for the resources they use without the need to over-provision for peak workloads. Existing ClickHouse users can migrate to ClickHouse Cloud with just a few simple steps, and new users can get started just as easily. ClickHouse Cloud features a robust partner integration ecosystem for data onboarding, data visualization, and language clients, further accelerating developer and analyst productivity.

“ClickHouse was built to enable our users to derive insights in real time from ever-increasing data volumes. Now the experience our open source users have loved for years is available in a simple and easy-to-use cloud service. It takes just a few minutes to get started, and the rich and growing ecosystem of integrations and partners makes it even easier to ingest and analyze data. We believe this intersection of incredibly high speed and amazingly efficient scale delivers critical advantages to our customers,” says Aaron Katz, co-founder and CEO of ClickHouse, Inc.

“With ClickHouse Cloud, our developers can go from concept to delivery on a new analytical feature in days, instead of weeks. And our operations teams do not have to spend cycles tuning cluster performance for even the most demanding workloads,” says Varun Krishnani of Adevinta. “Decoupled storage and compute architecture and usage-based pricing ensures that we don’t have to over-provision infrastructure, and as a result, our business moves even faster to deliver value to our users at a reduced cost.”

"We use ClickHouse Cloud to monitor millions of real-time web performance data points, to ensure we’re getting faster all the time,” says Daunish Aboobaker, VP Engineering at Minted. ”The platform delivers fast and reliable data management, while also proving to be cost efficient and user-friendly."

ClickHouse Cloud is available immediately in Public Beta. Join the hundreds of development teams that have already been using ClickHouse Cloud throughout the company's private preview and early access programs by signing up for a free trial at www.clickhouse.com.

About ClickHouse

ClickHouse is ​the world's fastest and most resource efficient online analytical ​column-oriented database management system​. Now offered as a secure and scalable serverless offering in the cloud, ClickHouse Cloud allows anyone to effortlessly take advantage of efficient real time analytical processing​. ​ Learn more at clickhouse.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005244/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye